lenalidomide has been researched along with African Lymphoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abro, B; Barnell, EK; Campbell, KM; Chavez, M; Cotto, KC; Duncavage, EJ; Fiala, MA; Frater, JL; Griffith, M; Griffith, OL; Hassan, A; King, JA; Kohnen, DR; Kreisel, F; Lee, YS; Newcomer, KF; Parikh, BA; Ruzinova, MB; Skidmore, ZL; Spies, NC; Uy, GL; Vij, K; Vij, R; Wang, T; Wartman, LD; Welch, JS | 1 |
| Bhatnagar, B; Dilip, D; Geyer, MB; Glass, JL; Hassoun, H; Klein, V; Landau, H; Lozanski, G; Mims, AS; Park, JH; Roshal, M; Shaffer, BC; Xiao, W; Zhang, Y | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
1 review(s) available for lenalidomide and African Lymphoma
| Article | Year |
|---|---|
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
3 other study(ies) available for lenalidomide and African Lymphoma
| Article | Year |
|---|---|
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.
Topics: Bone Marrow; Burkitt Lymphoma; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Lenalidomide; Multiple Myeloma; Mutation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2023 |
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
Topics: Aged; Burkitt Lymphoma; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; Retrospective Studies | 2023 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |